MIM
DYN icon

MetLife Investment Management’s Dyne Therapeutics DYN Stock Holding History

MetLife Investment Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32M Buy
72,841
+3,242
+5% +$55.9K 0.01% 1270
2025
Q4 		$1.36M Buy
69,599
+5,378
+8% +$102K 0.01% 1265
2025
Q3 		$812K Buy
64,221
+7,377
+13% +$84.1K ﹤0.01% 1576
2025
Q2 		$541K Buy
56,844
+8,048
+16% +$88.6K ﹤0.01% 1641
2025
Q1 		$510K Sell
48,796
-671
-1% -$9.6K ﹤0.01% 1714
2024
Q4 		$1.17M Buy
49,467
+2,748
+6% +$81.3K 0.01% 1333
2024
Q3 		$1.68M Hold
46,719
– – 0.01% 1116
2024
Q2 		$1.65M Buy
46,719
+16,237
+53% +$472K 0.01% 1069
2024
Q1 		$865K Buy
30,482
+7,549
+33% +$171K 0.01% 1378
2023
Q4 		$305K Hold
22,933
– – ﹤0.01% 1986
2023
Q3 		$205K Hold
22,933
– – ﹤0.01% 2191
2023
Q2 		$258K Buy
22,933
+3,167
+16% +$37.4K ﹤0.01% 2119
2023
Q1 		$228K Hold
19,766
– – ﹤0.01% 2138
2022
Q4 		$229K Hold
19,766
– – ﹤0.01% 2164
2022
Q3 		$251K Hold
19,766
– – ﹤0.01% 2140
2022
Q2 		$136K Hold
19,766
– – ﹤0.01% 2555
2022
Q1 		$191K Buy
19,766
+7,180
+57% +$61.1K ﹤0.01% 2380
2021
Q4 		$150K Hold
12,586
– – ﹤0.01% 2236
2021
Q3 		$204K Hold
12,586
– – ﹤0.01% 2092
2021
Q2 		$265K Buy
+12,586
New +$237K ﹤0.01% 1976
2021
Q1 		– Sell
-7,479
Closed -$157K – 2321
2020
Q4 		$157K Buy
+7,479
New +$148K ﹤0.01% 2108

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

MetLife Investment Management's DYN Position: Q1 2026 in Review

MetLife Investment Management increased its Dyne Therapeutics (DYN) stake by 4.7% in Q1 2026, buying an estimated $55.9K and bringing the position to 72,841 shares worth $1.32M. The position accounts for 0.01% of the portfolio, ranked #1270.

MetLife Investment Management first reported a position in DYN in Q4 2020 and has held it in 21 quarters since. The position peaked at $1.68M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • MetLife Investment Management held 72,841 shares of Dyne Therapeutics worth $1.32M as of Q1 2026.
  • MetLife Investment Management bought 3,242 Dyne Therapeutics shares in Q1 2026, an estimated $55.9K.
  • Dyne Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1270 holding.
  • MetLife Investment Management first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • MetLife Investment Management's Dyne Therapeutics position peaked at $1.68M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.